Clair Emerges to Build Hormone-Tracking Wearable
What happened
Clair, a new longevity-focused startup, has emerged from stealth with plans to launch a continuous, non-invasive hormone-tracking wearable. The device aims to provide real-time, needle-free hormonal insights. The product targets the growing interest in personalized health data for both chronic condition management and wellness optimization.
Why it matters
- The company was founded by Stanford graduates Jenny Duan and Abhinav Agarwal, who met in the spring of 2025 and began developing the technology. - Clair's wrist-worn device utilizes multimodal sensing, combining data from 10 biosensors that track over 500 biomarkers—including skin temperature, heart rate variability, and electrodermal activity—to infer hormone patterns. - To address privacy concerns, all data processing is designed to happen directly on the user's phone rather than being sent to external data centers, limiting third-party access to sensitive health information. - The company plans to pursue FDA approval to position the wearable as a medically credible device and is preparing for a clinical trial at Stanford Medicine. - The wearable aims to track levels of key hormones including estrogen, progesterone, LH, and FSH to provide insights for fertility, perimenopause, athletic performance, and managing hormonal health conditions. - Clair enters a competitive landscape of startups developing non-invasive hormone tracking, including Eli Health which uses at-home saliva tests and Oova which uses AI to analyze urine test strips. - The global femtech market, which Clair is a part of, was valued at over USD 9 billion in 2025 and is projected to grow to more than USD 41 billion by 2034. - Venture capital firm Reach Capital is an investor in the company, citing the need for tools that can capture and interpret hormonal data continuously and non-invasively.
Key numbers
- - The company was founded by Stanford graduates Jenny Duan and Abhinav Agarwal, who met in the spring of 2025 and began developing the technology.
- Clair's wrist-worn device utilizes multimodal sensing, combining data from 10 biosensors that track over 500 biomarkers—including skin temperature, heart rate variability, and electrodermal activity—to infer hormone patterns.
- The global femtech market, which Clair is a part of, was valued at over USD 9 billion in 2025 and is projected to grow to more than USD 41 billion by 2034.
What happens next
- The company plans to pursue FDA approval to position the wearable as a medically credible device and is preparing for a clinical trial at Stanford Medicine.
- The wearable aims to track levels of key hormones including estrogen, progesterone, LH, and FSH to provide insights for fertility, perimenopause, athletic performance, and managing hormonal health conditions.
- Clair, a new longevity-focused startup, has emerged from stealth with plans to launch a continuous, non-invasive hormone-tracking wearable.
Quick answers
What happened in Clair Emerges to Build Hormone-Tracking Wearable?
Clair, a new longevity-focused startup, has emerged from stealth with plans to launch a continuous, non-invasive hormone-tracking wearable. The device aims to provide real-time, needle-free hormonal insights. The product targets the growing interest in personalized health data for both chronic condition management and wellness optimization.
Why does Clair Emerges to Build Hormone-Tracking Wearable matter?
The company was founded by Stanford graduates Jenny Duan and Abhinav Agarwal, who met in the spring of 2025 and began developing the technology. Clair's wrist-worn device utilizes multimodal sensing, combining data from 10 biosensors that track over 500 biomarkers—including skin temperature, heart rate variability, and electrodermal activity—to infer hormone patterns. To address privacy concerns, all data processing is designed to happen directly on the user's phone rather than being sent to external data centers, limiting third-party access to sensitive health information. The company plans to pursue FDA approval to position the wearable as a medically credible device and is preparing for a clinical trial at Stanford Medicine. The wearable aims to track levels of key hormones including estrogen, progesterone, LH, and FSH to provide insights for fertility, perimenopause, athletic performance, and managing hormonal health conditions. Clair enters a competitive landscape of startups developing non-invasive hormone tracking, including Eli Health which uses at-home saliva tests and Oova which uses AI to analyze urine test strips. The global femtech market, which Clair is a part of, was valued at over USD 9 billion in 2025 and is projected to grow to more than USD 41 billion by 2034. Venture capital firm Reach Capital is an investor in the company, citing the need for tools that can capture and interpret hormonal data continuously and non-invasively.
